{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,9]],"date-time":"2026-01-09T10:12:09Z","timestamp":1767953529359,"version":"3.49.0"},"reference-count":19,"publisher":"Termedia Sp. z.o.o.","issue":"4","license":[{"start":{"date-parts":[[2021,12,3]],"date-time":"2021-12-03T00:00:00Z","timestamp":1638489600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-sa\/4.0\/"},{"start":{"date-parts":[[2021,12,3]],"date-time":"2021-12-03T00:00:00Z","timestamp":1638489600000},"content-version":"am","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-sa\/4.0\/"},{"start":{"date-parts":[[2021,12,3]],"date-time":"2021-12-03T00:00:00Z","timestamp":1638489600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-sa\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cent Eur J Immunol"],"abstract":"<jats:p>Mycosis fungoides (MF) is the most common subtype of primary cutaneous T cell lymphoma (CTCL). The erythrodermic form (T4) especially impairs health-related quality of life (HR-QoL), making patients often incapable of self-care. Mycosis fungoides and S\u00e9zary syndrome (SS) are immunogenic neoplasms and can be recognized by the patient\u2019s immune system. The disease is chronic and immunotherapy allows for long-term control of CTCL. The paper presents a description of 2 cases of nivolumab use in the salvage treatment of erythroderma in the course of refractory mycosis fungoides. Nivolumab was used as emergency treatment, and previously patients exhausted the available treatment options. The discussed cases confirm the effectiveness of immunotherapy in the treatment of primary cutaneous T cell lymphomas. The applied treatment achieved the effect of more than one year of response (15 months), as well as a significant benefit in terms of subjective and objective quality of life. The effect was mainly related to the condition of the skin. The use of the PD-1 checkpoint inhibitor allowed for over 12 months of control in advanced, refractory and heavily pretreated cutaneous lymphoma, and was very well tolerated. More research is needed on the use of such inhibitors in the treatment of cutaneous lymphomas.<\/jats:p>","DOI":"10.5114\/ceji.2021.111453","type":"journal-article","created":{"date-parts":[[2021,12,6]],"date-time":"2021-12-06T08:40:16Z","timestamp":1638780016000},"page":"535-538","source":"Crossref","is-referenced-by-count":3,"title":["Nivolumab in two cases of refractory mycosis fungoides erythroderma"],"prefix":"10.5114","volume":"46","author":[{"given":"Ewa","family":"Chmielowska","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"3061","published-online":{"date-parts":[[2021,12,3]]},"reference":[{"key":"ref-1540078","doi-asserted-by":"crossref","first-page":"3142","DOI":"10.1182\/blood-2015-12-611830","article-title":"How I treat mycosis fungoides and Sezary syndrome","volume":"127","author":"Whittaker S","year":"2016","unstructured":"Whittaker S, Hoppe R, Prince HM (2016): How I treat mycosis fungoides and Sezary syndrome. Blood 127: 3142-3153.","journal-title":"Blood"},{"key":"ref-1540079","doi-asserted-by":"crossref","first-page":"223.e1","DOI":"10.1016\/j.jaad.2013.08.033","article-title":"Primary cutaneous T-cell lymphoma (mycosis fungoides and S\u00e9zary syndrome): Part II. Prognosis, management, and future directions","volume":"70","author":"Jawed SI","year":"2014","unstructured":"Jawed SI, Myskowski PL, Horwitz S, et al. (2014): Primary cutaneous T-cell lymphoma (mycosis fungoides and S\u00e9zary syndrome): Part II. Prognosis, management, and future directions. J Am Acad Dermatol 70: 223.e1-17.","journal-title":"J Am Acad Dermatol"},{"key":"ref-1540080","doi-asserted-by":"crossref","first-page":"1243","DOI":"10.1111\/bjd.17194","article-title":"Infections in mycosis fungoides and S\u00e9zary syndrome are a frequent cause of morbidity and contribute to mortality","volume":"179","author":"Scarisbrick JJ","year":"2018","unstructured":"Scarisbrick JJ (2018): Infections in mycosis fungoides and S\u00e9zary syndrome are a frequent cause of morbidity and contribute to mortality. What can be done? Br J Dermatol 179: 1243-1244.","journal-title":"What can be done? Br J Dermatol"},{"key":"ref-1540081","article-title":"NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines\u00ae) Primary Cutaneous Lymphoma Version 1.2021 \u2013","year":"2020","unstructured":"NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines\u00ae) Primary Cutaneous Lymphoma Version 1.2021 \u2013October 12, 2020."},{"key":"ref-1540082","doi-asserted-by":"crossref","first-page":"iv30","DOI":"10.1093\/annonc\/mdy133","article-title":"on behalf of the ESMO Guidelines Committee (2018): Primary cutaneous lymphomas: ESMO clinical practice guidelines","volume":"29","author":"Willemze R","unstructured":"Willemze R, Hodak E, Zinzani PL, et al., on behalf of the ESMO Guidelines Committee (2018): Primary cutaneous lymphomas: ESMO clinical practice guidelines. Ann Oncol 29 (Suppl 4): iv30-iv40.","journal-title":"Ann Oncol"},{"key":"ref-1540083","doi-asserted-by":"crossref","first-page":"11","DOI":"10.21037\/cco.2019.01.01","article-title":"Immune evasion and current immunotherapy in mycosis fungoides (MF) and Sezary syndrome (SS)","volume":"8","author":"Shalabi D","year":"2019","unstructured":"Shalabi D, Bistline A, Alpdogan O, et al. (2019): Immune evasion and current immunotherapy in mycosis fungoides (MF) and Sezary syndrome (SS). Chin Clin Oncol 8: 11.","journal-title":"Chin Clin Oncol"},{"key":"ref-1540084","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1016\/j.ejca.2020.04.010","article-title":"Patient-reported quality of life in patients with relapsed\/refractory cutaneous T-cell lymphoma: Results from the randomised phase III ALCANZA study","volume":"133","author":"Dummer R","year":"2020","unstructured":"Dummer R, Prince HM, Whittaker S, et al. (2020): Patient-reported quality of life in patients with relapsed\/refractory cutaneous T-cell lymphoma: Results from the randomised phase III ALCANZA study. Eur J Cancer 133: 120-130.","journal-title":"Eur J Cancer"},{"key":"ref-1540085","doi-asserted-by":"crossref","first-page":"3747","DOI":"10.2147\/DDDT.S185896","article-title":"Spotlight on mogamulizumab-Kpkc for use in adults with relapsed or refractory mycosis fungoides or Sezary syndrome: efficacy, safety and patients selection","volume":"14","author":"Blackmon AL","year":"2020","unstructured":"Blackmon AL, Pinter-Brown L (2020): Spotlight on mogamulizumab-Kpkc for use in adults with relapsed or refractory mycosis fungoides or Sezary syndrome: efficacy, safety and patients selection. Drug Des Devel Ther 14: 3747-3754.","journal-title":"Drug Des Devel Ther"},{"key":"ref-1540086","doi-asserted-by":"crossref","first-page":"116","DOI":"10.3389\/fmed.2019.00116","article-title":"Novel and future therapeutic drugs for advanced mycosis fungoides and Sezary syndrome","volume":"6","author":"Oka T","year":"2019","unstructured":"Oka T, Miyagaki T (2019): Novel and future therapeutic drugs for advanced mycosis fungoides and Sezary syndrome. Front Med 2019; 6: 116.","journal-title":"Front Med"},{"key":"ref-1540087","doi-asserted-by":"crossref","first-page":"2698","DOI":"10.1200\/JCO.2015.65.9789","article-title":"Nivolumab in patients with relapsed or refractory hematologic malignancy: preliminary results of a phase Ib study","volume":"34","author":"Lesokhin AM","year":"2016","unstructured":"Lesokhin AM, Ansell SM, Armand P, et al. (2016): Nivolumab in patients with relapsed or refractory hematologic malignancy: preliminary results of a phase Ib study. J Clin Oncol 34: 2698-2704. D\u00f3\u0142 formularzaPocz\u0105tek formularza","journal-title":"J Clin Oncol"},{"key":"ref-1540088","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1200\/JCO.19.01056","article-title":"Pembrolizumab in relapsed and refractory mycosis fungoides and s\u00e9zary syndrome: a multicenter phase II study","volume":"38","author":"Khodadoust MS","year":"2020","unstructured":"Khodadoust MS, Rook AH, Porcu P, et al. (2020): Pembrolizumab in relapsed and refractory mycosis fungoides and s\u00e9zary syndrome: a multicenter phase II study. J Clin Oncol 38: 20-28.","journal-title":"J Clin Oncol"},{"key":"ref-1540089","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/j.jdcr.2020.10.025","article-title":"Pembrolizumab and palliative radiotherapy in 2 cases of refractory mycosis fungoides","volume":"7","author":"Walker CJ","year":"2020","unstructured":"Walker CJ, Donnelly ED, Moreira J, et al. (2020): Pembrolizumab and palliative radiotherapy in 2 cases of refractory mycosis fungoides. JAAD Case Rep 7: 87-90.","journal-title":"JAAD Case Rep"},{"key":"ref-1540090","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/j.jdcr.2015.02.009","article-title":"Complete regression of mycosis fungoides after ipilimumab therapy for advanced melanoma","volume":"1","author":"Bar-Sela G","year":"2015","unstructured":"Bar-Sela G, Bergman R (2015): Complete regression of mycosis fungoides after ipilimumab therapy for advanced melanoma. JAAD Case Rep 1: 99-100.","journal-title":"JAAD Case Rep"},{"key":"ref-1540091","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1177\/1203475419867610","article-title":"Immunotherapy for cutaneous T-cell lymphoma: current landscape and future developments","volume":"23","author":"Sivanand A","year":"2019","unstructured":"Sivanand A, Surmanowicz PH, Alhusayen R, et al. (2019): Immunotherapy for cutaneous T-cell lymphoma: current landscape and future developments. J Cut Med Sur 23: 537-544.","journal-title":"J Cut Med Sur"},{"key":"ref-1540092","doi-asserted-by":"crossref","first-page":"Abst 15680","DOI":"10.1016\/j.annonc.2020.08.2051","article-title":"Quality of life in cancer patients treated with immune checkpoint inhibitors: A meta-analysis","volume":"31","author":"Gonzalez BD","year":"2020","unstructured":"Gonzalez BD, Eisel SL, Bowles KE, et al. (2020): Quality of life in cancer patients treated with immune checkpoint inhibitors: A meta-analysis. Ann Oncol 31 (Suppl 4): Abst 15680.","journal-title":"Ann Oncol"},{"key":"ref-1540093","doi-asserted-by":"crossref","first-page":"F1000faculty Rev-331","DOI":"10.12688\/f1000research.21922.1","article-title":"Recent advances in understanding and managing cutaneous T-cell lymphomas","volume":"9","author":"Brunner PM","year":"2020","unstructured":"Brunner PM, Jonak C, Knobler R (2020): Recent advances in understanding and managing cutaneous T-cell lymphomas. F1000Res 9: F1000faculty Rev-331.","journal-title":"F1000Res"},{"key":"ref-1540094","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1080\/0284186X.2020.1712473","article-title":"Comparative-effectiveness of pembrolizumab vs. nivolumab for patients with metastatic melanoma","volume":"59","author":"Moser J","year":"2020","unstructured":"Moser J, Wei G, Colonna S, et al. (2020): Comparative-effectiveness of pembrolizumab vs. nivolumab for patients with metastatic melanoma. Acta Oncol 59: 434-437.","journal-title":"Acta Oncol"},{"key":"ref-1540095","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1007\/s12185-017-2181-9","article-title":"Successful treatment with low-dose nivolumab in refractory Hodgkin lymphoma after allogeneic stem cell transplantation","volume":"106","author":"Onizuka M","year":"2017","unstructured":"Onizuka M, Kojima M, Matsui K, et al. (2017): Successful treatment with low-dose nivolumab in refractory Hodgkin lymphoma after allogeneic stem cell transplantation. Int J Hematol 106: 141-145.","journal-title":"Int J Hematol"},{"key":"ref-1540096","doi-asserted-by":"crossref","first-page":"1193","DOI":"10.3389\/fonc.2020.01193","article-title":"Extended-interval dosing strategy of immune checkpoint inhibitors in lung cancer: will it outlast the COVID-19 pandemic","volume":"10","author":"Sehgal K","year":"2020","unstructured":"Sehgal K, Costa D, Rangachari D (2020): Extended-interval dosing strategy of immune checkpoint inhibitors in lung cancer: will it outlast the COVID-19 pandemic. Front Oncol 10: 1193.","journal-title":"Front Oncol"}],"container-title":["Central European Journal of Immunology"],"original-title":[],"link":[{"URL":"https:\/\/ceji.termedia.pl\/pdf-143750-129685","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/ceji.termedia.pl\/pdf-143750-129685","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,9]],"date-time":"2026-01-09T08:33:27Z","timestamp":1767947607000},"score":1,"resource":{"primary":{"URL":"https:\/\/ceji.termedia.pl\/Nivolumab-in-two-cases-of-refractory-mycosis-fungoides-erythroderma,143750,0,2.html"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,12,3]]},"references-count":19,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2021]]}},"alternative-id":["143750"],"URL":"https:\/\/doi.org\/10.5114\/ceji.2021.111453","relation":{},"ISSN":["1426-3912","1644-4124"],"issn-type":[{"value":"1426-3912","type":"print"},{"value":"1644-4124","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,12,3]]}}}